is tirzepatide mounjaro FDA approves new version of diabetes drug to be sold for weight loss Mounjaro is second obesity drug

Although the weight loss is considered clinically significant according to the clinical expert consulted by CADTH on this review, there is no clear evidence that this weight loss reduces the number of patients who may develop various weight-related comorbidities, including type 2 diabetes, cardiovascular disease, and osteoarthritis

Although 45% of dNETs stained positively for GLP-1R, the mean intensity score (H-score) was modest at 57

This practice not only helps manage discomfort but also promotes better treatment outcomes

Missing data information was requested by email from the corresponding authors

Here is a quick guide to understanding post-injection inflammation and how to manage it